Vaxart Return on Equity (ROE) Growth & History (VXRT)
Vaxart's return on equity was 22.26% for fiscal 2025.
View full Vaxart company overviewVaxart annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 22.26% | +136.96 pp |
| 2024 | 2024-12-31 | −114.71% | −16.77 pp |
| 2023 | 2023-12-31 | −97.94% | −25.65 pp |
| 2022 | 2022-12-31 | −72.29% | −26.96 pp |
| 2021 | 2021-12-31 | −45.33% | +1.93 pp |
| 2020 | 2020-12-31 | −47.26% | +107.07 pp |
| 2019 | 2019-12-31 | −154.33% | — |
| 2017 · Jun 30 | 2017-06-30 | −90.60% | −46.69 pp |
| 2016 | 2016-06-30 | −43.91% | −19.48 pp |
| 2015 | 2015-06-30 | −24.42% | −10.22 pp |
| 2014 | 2014-06-30 | −14.20% | −0.22 pp |
| 2013 | 2013-06-30 | −13.98% | +16.33 pp |
| 2012 | 2012-06-30 | −30.31% | +5.47 pp |
| 2011 · Dec 31 | 2011-12-31 | −6.09% | −7.20 pp |
| 2011 · Jun 30 | 2011-06-30 | −35.78% | — |
| 2010 | 2010-12-25 | 1.11% | — |
Vaxart quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.29% | +22.89 pp |
| Q1 2026 | 2026-03-31 | 5.69% | +35.52 pp |
| Q4 2025 | 2025-12-31 | 96.10% | +114.92 pp |
| Q3 2025 | 2025-09-30 | −27.30% | −8.33 pp |
| Q2 2025 | 2025-06-30 | −38.18% | −13.92 pp |
| Q1 2025 | 2025-03-31 | −29.83% | +13.20 pp |
| Q4 2024 | 2024-12-31 | −18.82% | +8.05 pp |
| Q3 2024 | 2024-09-30 | −18.97% | +3.25 pp |
| Q2 2024 | 2024-06-30 | −24.27% | +1.53 pp |
| Q1 2024 | 2024-03-31 | −43.03% | −17.93 pp |
| Q4 2023 | 2023-12-31 | −26.87% | −6.33 pp |
| Q3 2023 | 2023-09-30 | −22.22% | −0.14 pp |
| Q2 2023 | 2023-06-30 | −25.80% | −6.78 pp |
| Q1 2023 | 2023-03-31 | −25.10% | −10.91 pp |
| Q4 2022 | 2022-12-31 | −20.54% | −9.96 pp |
| Q3 2022 | 2022-09-30 | −22.09% | −13.40 pp |
| Q2 2022 | 2022-06-30 | −19.02% | −10.45 pp |
| Q1 2022 | 2022-03-31 | −14.19% | −3.50 pp |
| Q4 2021 | 2021-12-31 | −10.58% | +0.29 pp |
| Q3 2021 | 2021-09-30 | −8.69% | +0.72 pp |
| Q2 2021 | 2021-06-30 | −8.57% | +16.53 pp |
| Q1 2021 | 2021-03-31 | −10.68% | −4.82 pp |
| Q4 2020 | 2020-12-31 | −10.87% | +29.37 pp |
| Q3 2020 | 2020-09-30 | −9.41% | +20.87 pp |
| Q2 2020 | 2020-06-30 | −25.10% | +14.57 pp |
| Q1 2020 | 2020-03-31 | −5.86% | +5.40 pp |
| Q4 2019 | 2019-12-31 | −40.24% | −4.19 pp |
| Q3 2019 | 2019-09-30 | −30.28% | +3.88 pp |
| Q2 2019 | 2019-06-30 | −39.67% | −6.48 pp |
| Q1 2019 | 2019-03-31 | −11.26% | — |
| Q4 2018 | 2018-12-31 | −36.05% | — |
| Q3 2018 | 2018-09-30 | −34.16% | −20.83 pp |
| Q2 2018 | 2018-06-30 | −33.19% | −16.69 pp |
| Q1 2018 · Sep 30 | 2017-09-30 | −13.33% | +10.82 pp |
| Q4 2017 · Jun 30 | 2017-06-30 | −16.49% | −2.14 pp |
| Q3 2017 | 2017-03-31 | −10.71% | −1.28 pp |
| Q2 2017 | 2016-12-31 | −28.17% | −17.43 pp |
| Q1 2017 | 2016-09-30 | −24.15% | −14.23 pp |
| Q4 2016 | 2016-06-30 | −14.36% | +12.00 pp |
| Q3 2016 | 2016-03-31 | −9.44% | −10.90 pp |
| Q2 2016 | 2015-12-31 | −10.74% | −18.85 pp |
| Q1 2016 | 2015-09-30 | −9.92% | −1.55 pp |
| Q4 2015 | 2015-06-30 | −26.36% | −15.20 pp |
| Q3 2015 | 2015-03-31 | 1.46% | −2.53 pp |
| Q2 2015 | 2014-12-31 | 8.11% | +8.26 pp |
| Q1 2015 | 2014-09-30 | −8.37% | −2.50 pp |
| Q4 2014 | 2014-06-30 | −11.15% | −2.38 pp |
| Q3 2014 | 2014-03-31 | 4.00% | +3.74 pp |
| Q2 2014 | 2013-12-31 | −0.15% | −8.60 pp |
| Q1 2014 | 2013-09-30 | −5.87% | +10.26 pp |
| Q4 2013 | 2013-06-30 | −8.78% | −4.17 pp |
| Q3 2013 | 2013-03-31 | 0.25% | +3.46 pp |
| Q2 2013 | 2012-12-31 | 8.45% | +19.46 pp |
| Q1 2013 | 2012-09-30 | −16.13% | −16.24 pp |
| Q4 2012 | 2012-06-30 | −4.60% | +3.04 pp |
| Q1 2012 · Mar 31 | 2012-03-31 | −3.21% | — |
| Q4 2011 | 2011-12-31 | −11.02% | — |
| Q1 2012 · Sep 24 | 2011-09-24 | 0.11% | — |
| Q2 2011 | 2011-06-25 | −7.65% | — |
Vaxart return on equity trends
Over the last five fiscal years, Vaxart's return on equity increased from −47.26% to 22.26%, a change of +69.51 percentage points. The latest reported quarter, Q2 2026, shows −15.29%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxart source filings ↗